Intersect ENT (XENT) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Intersect ENT Reports Fourth Quarter and Year 2015 Results
February 23, 2016 4:05 PM ESTFull Year Revenue Increased 60% Year Over Year; Gross Margin at 80%
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year ended December 31, 2015.
Fourth quarter revenue was $18.8 million, representing a 40% increase over the fourth quarter 2014. Full year 2015 revenue was $61.6 million, representing a 60% increase over full year 2014. Fourth quarter gross margin was 80% compared to 78%... MoreIntersect ENT Appoints David Lehman General Counsel
February 22, 2016 4:05 PM ESTMENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of David Lehman as general counsel. Mr. Lehman brings three decades of legal experience to Intersect ENT, most recently having served as general counsel and secretary for Thoratec Corporation (NASDAQ: THOR), a global leader in medical technology to address advanced-stage heart failure, where he saw the company through tremendous growth and eventual sale to St. Jude... More
